6-[(3,4-dimethoxy-2-pyridyl)-methylthio]-5H-[1,3]-dioxolo[4,5-f]benzimidazole | 102625-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 6-[(3,4-dimethoxy-2-pyridyl)-methylthio]-5H-[1,3]-dioxolo[4,5-f]benzimidazole
• 英文别名: 6-[(3,4-dimethoxypyridin-2-yl)methylsulfanyl]-5H-[1,3]dioxolo[4,5-f]benzimidazole
• CAS: 102625-76-3
• 化学式: C₁₆H₁₅N₃O₄S
• 分子量: 345.379
• InChiKey: OXNPSVHHMPDGDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-Mercapto-5,6-methylendioxy-benzimidazol 、 2-氯甲基-3,4-二甲氧基吡啶盐酸盐 生成 6-[(3,4-dimethoxy-2-pyridyl)-methylthio]-5H-[1,3]-dioxolo[4,5-f]benzimidazole
  参考文献：
  名称：

  Fluoroalkoxy substituted benzimidazoles useful as gastric acid secretion

  摘要：

  式I的二烷氧基吡啶##STR1##其中R1是完全或主要由氟或氯二氟甲基取代的1-3C-烷基，R1'是氢、卤素、三氟甲基、1-3C-烷基或1-3C-烷氧基，后者可以选择性地完全或主要由氟取代，或R1和R1'连同与R1连接的氧原子一起，是1-2C-烷二氧基，后者可以选择性地完全或部分由氟取代，或氯三氟乙烯二氧基，R3是1-3C-烷氧基，R2和R4中的一个是1-3C-烷氧基，另一个是氢原子或1-3C-烷基，n为0或1，以及它们的盐是一种对胃具有显著保护作用的新化合物。揭示了制备这些化合物的方法，含有它们的药物及其用途，以及中间体化合物及其用途用于制备所述二烷氧基吡啶。

  公开号：

  US04758579A1

文献信息

• Dialkoxypyridine, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende Arzneimittel
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：EP0166287B1

  公开（公告）日：1989-08-23
• COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS
  申请人：Atopix Therapeutics Limited

  公开号：EP2790696A1

  公开（公告）日：2014-10-22
• Method of treating snoring and other obstructive breathing disorders
  申请人：——

  公开号：US20040258621A1

  公开（公告）日：2004-12-23

  A method of pharmaceutically managing snoring and impaired breathing is provided. This invention relates to treating snoring, sleep apnea, and other forms of sleep-disordered breathing in those with or without symptoms of or the diagnosis of gastro-intestinal reflux disease (GERD). It comprises administration of a therapeutically effective dose of Prevacid (Lansoprazole) or any other medication that can be used to treat symptoms of hyper-acidity or gastrointestinal reflux disease (GERD). The therapeutic medication may be used alone or in combination with other pharmacologic agents or mechanical modalities including but not limited to decongestants, antihistamines or mechanical nasal toilet. It also is of benefit in improving breathing disorders that are present while awake.
• Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
  申请人：Atopix Therapeutics Limited

  公开号：US20140328861A1

  公开（公告）日：2014-11-06

  Disclosed are methods and compositions for preventing, treating, or ameliorating eosinophilic esophagitis (EoE) in an individual, comprising administering to the individual a therapeutically effective amount of at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor (PPI) or a pharmaceutically acceptable salt thereof. Also disclosed are compositions comprising at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor or a pharmaceutically acceptable salt thereof.
• US4758579A
  申请人：——

  公开号：US4758579A

  公开（公告）日：1988-07-19